Chronic smoking, but not acute nicotine administration, modulates neural correlates of working memory.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a controlled clinical trial.

In an effort to elucidate potential enhancing effects, the researchers explored the impact of transdermal nicotine on neural functioning in minimally deprived smokers and, in addition, assessed differences between smokers and non-smokers using a mixed block/event-related fMRI design that attempted to isolate specific central executive operations (attentional switch events) within general WM function (task blocks).

Why It Was Studied

Beyond the amelioration of deprivation-induced impairments, and in contrast to effects on attentional processes, the cognitive-enhancing properties of nicotine on working memory (WM) operations remain unclear.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In task blocks, participants performed a continuous counting paradigm that required the simultaneous maintenance of, and frequent switching of attentional focus between, two running tallies in WM on some trials.

How the Study Was Run

The researchers set it up as a placebo-controlled study.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Cigarette smokers (n = 30) were scanned twice, once each with a nicotine and placebo patch, while non-smokers (n = 27) were scanned twice with no patch.

What Was Measured

PubMed files the paper under topics including Administration, Cutaneous, Brain, Executive Function, Magnetic Resonance Imaging, Memory, Short-Term, Nicotine and Psychomotor Performance.

What This Means in Plain Language

The paper is a placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2011 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.